The FDA approved AstraZeneca’s Baxfendy (baxdrostat), a first-in-class aldosterone synthase inhibitor, as a new add-on option for hypertension patients not adequately controlled on existing therapy. The approval is based on results from the phase 3 BaxHTN study, which met primary and secondary endpoints. AstraZeneca is positioning Baxfendy as a potential growth driver as parts of its cardiometabolic portfolio face patent pressure. The approval also sets up potential near-term competitive dynamics, with Mineralys Therapeutics’ aldosterone synthase inhibitor lorundrostat listed for a December 2026 PDUFA date. The labeling and uptake trajectory will be closely watched because aldosterone synthase inhibition represents a distinct mechanism compared with many current antihypertensive classes, with real-world adoption likely dependent on tolerability, differentiated efficacy, and prescribing preferences. Regulators’ mechanism-specific approvals like this can also shape payer coverage decisions and influence how quickly other programs in the same target space move toward late-stage filings.